Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

The market potential of a likely soon to be approved Afrezza. Will this launch be different (better) than Exubera?

Ticker(s): MNKD, NVO, PFE, LLY

Who's the expert?

Name: Blinded Expert

Bio:

  • Endocrinologist in practice for over 20 years with significant experience with rapid acting insulin, including Exubera and Afrezza.
  • Treats approximately 300 diabetics patients per month of which 90% of her patients are Type II diabetics and 10% are Type 1.

Interview Questions
Q1.

How many diabetics do you currently treat?

Added By: joe_mccann
Q2.

Did you use Exubera when it was on the market? What was your opinion of it?

Added By: joe_mccann
Q3.

Are you open to trying Afrezza in your patients assuming it gets approved by the FDA?

Added By: joe_mccann
Q4.

How much of an issue/impression did the Exubera failure leave on the physician and patient mindset about a new inhaled option.

Added By: joe_mccann
Q5.

Does the improved device for Afrezza improve its appeal to you?

Added By: joe_mccann
Q6.

How much of a hindrance would a lung function test requirement be for prescribing in your practice?

Added By: joe_mccann
Q7.

What percent of your diabetic patients are smokers? Would you give this option to those patients?

Added By: joe_mccann
Q8.

How do you anticipate using the product in the first 6 months and 12 months once it is available?

Added By: joe_mccann
Q9.

What would be a "show stopper" or significantly limit your interest in the product if it showed up in the label?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.